Global burden of chronic pulmonary aspergillosis complicating sarcoidosis
Global burden of chronic pulmonary aspergillosis complicating sarcoidosis
复制标题
DOI：
10.1183/09031936.00226911
复制
发表时间：
2013-03-01
影响因子：
24.3
通讯作者：
Cole, Donald C.
中科院分区：
文献类型：
--
作者：
Denning, David W.;Pleuvry, Alex;Cole, Donald C.
慢性肺曲菌病（CPA）可能使肺结节病并发。我们重新估计了结节病的全球负担和CPA并发结节病的负担。我们检索了文献和检索到的论文的参考文献列表，以确定所有已发表的结节病发病率和患病率数据。我们从11篇涉及> 3，000例结节病患者的论文中估计了CPA的频率，以得出CPA患者数量。我们采用15%的年流失率（范围10-25%）来估计CPA的全球负担。我们估计，结节病的年发病率为344，000例患者，患病率与1，238，000例相似，分布如下：欧洲165，979例，美洲224，000例，非洲492，892例，东地中海80，023例，西太平洋41，660例，东南亚234，010例。CPA在3-12%的病例中并发结节病。使用6%的频率，我们估计全球负担为71，907（范围35，954 - 143，815（3-12%））CPA病例并发结节病，估计有24%和37%的病例存在于美洲和非洲，因为黑人结节病的发病率较高。对肺结节病患者进行定期CPA筛查可能很重要，尤其是对需要皮质类固醇治疗的患者。
Chronic pulmonary aspergillosis (CPA) may complicate pulmonary sarcoidosis. We re-estimated the global burden of sarcoidosis and the burden of CPA complicating sarcoidosis.We searched the literature and reference lists of retrieved papers to identify all published sarcoidosis incidence and prevalence data.We estimated the frequency of CPA from 11 papers relating to >3,000 patients with sarcoidosis to derive CPA patient numbers. We applied an annual attrition rate of 15% (range 10-25%) to estimate the global burden of CPA. We estimate that the annual incidence of sarcoidosis is 344,000 patients worldwide and the prevalence is similar to 1,238,000 cases, distributed as follows: 165,979 in Europe, 224,000 in the Americas, 492,892 in Africa, 80,023 in the Eastern Mediterranean, 41,660 in the West Pacific and 234,010 in Southeast Asia. CPA complicates sarcoidosis in 3-12% of cases. Using a 6% frequency, we estimate a global burden of 71,907 (range 35,954-143,815 (3-12%)) CPA cases complicating sarcoidosis, with 24% and 37% of cases estimated to be present in the Americas and Africa, because of the higher incidence of sarcoidosis in black people.As CPA responds to long-term antifungal therapy, which may prevent life-threatening haemoptysis, screening periodically for CPA in those with pulmonary sarcoidosis may be important, especially in patients requiring corticosteroid therapy.